Mablink Bioscience to Present Promising Preclinical Data

Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023

  • In vivo antitumor efficacy with significant tumor growth inhibition in multiple models with varying levels of FOLR1 expression
  • Highly promising safety results in non-human primates, enabling a broad therapeutic window
  • High conjugation yields, along with 100% DAR8 homogeneity and stability, major drivers of the successful ongoing manufacturing process
  • IND submission planned in Q4 2023

Lyon - France, March 14, 2023 (22h30 CET)

Mablink Bioscience (“Mablink”), a biotechnology company dedicated to advancing cancer therapy with next-generation antibody-drug conjugates (ADCs), today announced that preclinical efficacy and safety data on its lead ADC candidate, MBK-103, will be presented at the American Association for Cancer Research (“AACR“) Meeting 2023 on April 17, 2023, in Orlando, Florida.

Mablink's poster will include in vivo efficacy data in mouse models and safety data in non-human primates (see abstract).

Mablink presented the proof-of-concept results it obtained with its proprietary ADC platform PSARLink™ in previous scientific articles and posters. PSARLink™ ADCs present an enhanced hydrophilicity and plasma-stability which translates into an improved tolerability and a prolonged half-life, similar to the unconjugated antibody. The increased drug-exposure in rodent models correlates with an improved anti-tumoral efficacy.

MBK-103 is the first development candidate coming from the PSARLink™ platform and it confirms the pharmacological improvement observed in the PoC experiments.

MBK-103, an antibody-drug conjugate targeting the Folate receptor alpha (FOLR1 or FRα), demonstrated excellent ex vivo stability in human plasma, which should lead to a lower off-target toxicity.
Significant tumor growth inhibition was achieved in more than 10 in vivo mouse tumor models at low doses (1-3 mg/kg) with varying levels of FRα expression. The distinct mode of action of exatecan (anti-topo-I, the payload) and the unique characteristics of the proprietary drug-linker platform resulted in potent anti-tumor efficacy obtained notably in colorectal cancer, where tubulin inhibitors have shown poor therapeutic efficacy.
The compound was also well tolerated in cynomolgus monkeys at the highest non-severely toxic dose (HNSTD) of 50 mg/kg administered repeatedly. These promising data are a significant differentiator in the ADC’s landscape.
High conjugation yields along with 100% homogeneity are key drivers of the successful ongoing manufacturing process in preparation of initiating clinical trials, since Mablink plans to submit a Clinical Trial Application (CTA)in the fourth quarter of 2023.

“We are excited about MBK-103 as a new generation ADC therapeutic candidate driven by a promising therapeutic index,” said Jean-Guillaume Lafay, CEO of Mablink, “Our ongoing IND-enabling study program to support first-in-human trials with MBK-103 is delivering as expected and we plan to submit our CTA in the fourth quarter of 2023.

Details about the poster presentation

Title: MBK-103, a potent novel conjugation platform-based antibody-drug conjugate, changing therapeutic options in folate receptor alpha positive cancer patients

Poster Board number: 24
Abstract Presentation Number: 1544
Presenter: Lenka Kyrych Sadilkova, PhD
Session category: Experimental and Molecular Therapeutics
Session title: Antibody Drug Conjugates
Session date and time: Monday Apr 17, 2023, 9:00 AM - 12:30 PM

About Mablink Bioscience

Mablink Bioscience is a biotechnology company developing the next generation of an emerging class of cancer drugs called antibody-drug conjugates (ADCs). Mablink’s patented hydrophilic drug-linker technology, PSARLinkTM, enables the design of homogeneous, plasma-stable, next generation ADCs with high DAR (drug-to-antibody ratio) while maintaining excellent pharmacological properties and tolerability.

For more information, please visit https://mablink.com

About MBK-103

MBK-103, an antibody-drug conjugate targeting the Folate receptor alpha (FOLR1 or FRα), is based on Mablink’s PSARLinkTM proprietary hydrophilic drug-linker platform. It consists of: (i) an Fc-attenuated humanized IgG1 monoclonal antibody, that binds selectively to FRα; (ii) a polysarcosine hydrophobicity masking entity that allows for a high drug-antibody-ratio (DAR) of 8, while improving the pharmacokinetics and tolerability of the drug; (iii) a proprietary dipeptide cleavable unit and (iv) exatecan, a potent topoisomerase I inhibitor as the payload.

FRα is a clinically validated target, that is overexpressed extracellularly in numerous solid tumors with high unmet medical need. Ovarian, non-small cell lung and breast adenocarcinoma are among the indications with the highest frequency of FRα-positive patients with every second patient showing upregulated topoisomerase I expression.



Mablink Bioscience to Present Promising Preclinical Data

TIN LIÊN QUAN

Tango Therapeutics to Highlight Preclinical Data on

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster...

Sana Biotechnology Announces the Acceptance of Four

Late-breaking poster presentation to highlight preclinical data demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR gene...

Small Pharma to Host Virtual Roundtable Event with Key

LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company...

Notice of the Annual General Meeting 2023 of Copenhagen

Notice is hereby given of the Annual General Meeting of Copenhagen Airports A/S to be held on Thursday, 30 March 2023 at 3:00 pm. The notice, including...

AIM ImmunoTech to Participate in Solve M.E. and The

OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the...

Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice:

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all...

05/2023 Green Hydrogen Systems announces changes to its

Company announcement 05/2023 Green Hydrogen Systems announces changes to its Board of Directors Kolding, Denmark, 1 March 2023 – In connection with...

THỦ THUẬT HAY

Hướng dẫn cách hẹn giờ gửi email trên iPhone/ iPad

Thủ thuật hẹn giờ gửi email trên iPhone, iPad là vô cùng cần thiết khi chúng ta cần gửi email cho khách hàng đúng giờ hay gửi emal chúc mừng sinh nhật… Việc này sẽ rất hữu ích khi bạn chỉ cần soạn trước nội dung và

Khắc phục lỗi mất âm thanh khi gọi điện thoại Samsung

Nhiều người dùng báo cáo rằng khi họ đang sử dụng các sản phẩm thuộc dòng Galaxy của Samsung, họ thường xuyên gặp phải lỗi mất âm thanh khi gọi điện thoại.

Cách cài đặt themes "Tiểu Cương Thi" đang hot trên Android

Vừa qua mình đã giới thiệu đến bạn bộ ảnh cực dễ thương của Tiểu Cương Thi, tiếp nối series sẽ là hướng dẫn cài đặt themes của nhân vật này lên điện thoại Android.

Hướng dẫn đăng ký giao dịch BHXH điện tử

Để thực hiện các giao dịch BHXH trực tuyến thông qua Cổng thông tin điện tử BHXH Việt Nam, bạn cần đăng ký tài khoản giao dịch với cơ quan BHXH. Sau khi có tài khoản mới tiến hành nộp hồ sơ, tra cứu hồ sơ BHXH trực

Viber thừa nhận mắc lỗ hổng nghiêm trọng

NDĐT - Hơn 50 triệu người sử dụng smartphone trên toàn cầu, trong đó có 3,5 triệu người Việt Nam, đứng trước nguy cơ bị xâm nhập bởi một lỗi nghiêm trọng trong ứng dụng Viber.

ĐÁNH GIÁ NHANH

Jaguar F-Type S Convertible: Hiệu năng cao, vẻ đẹp ấn tượng và trải nghiệm lái choáng ngợp

Có nhiều yếu tố khiến Jaguar E-Type được tôn thờ và ca ngợi bởi cả fan cuồng của hãng xe Anh và những nhà báo, nhà thiết kế khó tính nhất. Đó có thể là tốc độ tối đa 240 km/h thuộc hàng

4 tính năng đáng chú ý trên iPhone 13 Series

iPhone 13 Series đã chính thức được ra mắt. Tuy chúng không có nhiều đột phá trong thiết kế nhưng lại được nâng cấp nhiều về phần cứng và tính năng. Vậy đâu là những tính năng đáng chú ý trên iPhone 13 series? Cùng

Có 50 triệu đồng nên chọn iPhone 13 Pro Max 1TB hay Galaxy Z Fold3 5G?

Cả iPhone 13 Pro Max và Galaxy Z Fold3 5G đều là những chiếc smartphone cao cấp nhất hiện nay. Giá bán của hai thiết bị này không hề rẻ. Vậy nếu có trong tay 50 triệu đồng thì nên chọn iPhone 13 Pro Max 1TB hay Galaxy